Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 6, 2007, Pages 821-827

  Isbister, G K ^a,b   Friberg, L E ^c   Hackett, L P ^d   Duffull, S B ^e  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c UPPSALA UNIVERSITY   (Sweden)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; CARBAMAZEPINE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; QUETIAPINE;

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG OVERDOSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIDOTES; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; CHARCOAL; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; OVERDOSE; UNCERTAINTY;

EID: 34249045416     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100193     Document Type: Article

References (23)

1. Friberg, L.E., Isbister, G.K., Hackett, L.P. & Duffull, S.B. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J. Pharmacokinet. Pharmacodyn. 32, 571-605 (2005).
2. Anderson, B.J., Holford, N.H., Armishaw, J.C. & Aicken, R. Predicting concentrations in children presenting with acetaminophen overdose. J. Pediatr. 135, 290-295 (1999).
3. Friberg, L.E., Isbister, G.K. & Duffull, S.B. Pharmacokinetic- pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br. J. Clin. Pharmacol. 61, 177-190 (2006).
4. Balit, C.R., Isbister, G.K., Hackett, L.P. & Whyte, I.M. Quetiapine poisoning: a case series. Ann. Emerg. Med. 42, 751-758 (2003).
5. Mowry, J., Sanftleben, J. & Smith, J. Eighteen month retrospective evaluation of seroquel exposures [abstract]. J. Toxicol. Clin. Toxicol. 37, 631 (1999).
6. Lynch, S., Fill, S. & Hoffman, R.S. Intentional quetiapine (seroquel) overdose [abstract]. J. Toxicol. Clin. Toxicol. 631 (1999).
7. Hunfeld, N.G. et al Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. Ther. Drug Monit. 28, 185-189 (2006).
8. Pollak, P.T. & Zbuk, K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin. Pharmacol. Ther. 68, 92-97 (2000).
9. DeVane, C.L. & Nemeroff, C.B. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet. 40, 509-522 (2001).
10. Li, K.Y., Li, X., Cheng, Z.N. & Li, H.D. Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose. Methods Find. Exp. Clin. Pharmacol. 27, 83-86 (2005).
11. Kimko, H.C., Reele, S.S., Holford, N.H. & Peck, C.C. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin. Pharmacol. Ther. 68, 568-577 (2000).
12. Thyrum, P.T., Wong, Y.W. & Yeh, C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry 24, 521-533 (2000).
13. Jaskiw, G.E., Thyrum, P.T., Fuller, M.A., Arvanitis, L.A. & Yeh, C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin. Pharmacokinet. 43, 1025-1035 (2004).
14. Wong, Y.W., Yeh, C. & Thyrum, P.T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J. Clin. Psychopharmacol. 21, 89-93 (2001).
15. Li, K.Y. et al Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur. J. Clin. Pharmacol. 60, 791-795 (2005).
16. Dansirikul, C., Morris, R.G., Tett, S.E. & Duffull, S.B. A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br. J. Clin. Pharmacol. 62, 420-434 (2006).
17. Chyka, P.A., Seger, D., Krenzelok, E.P. & Vale, J.A. Position paper: single-dose activated charcoal. Clin. Toxicol. (Philadelphia) 43, 61-87 (2005).
18. Spiegelhalter, D.J., Thomas, A. & Best, N.G. WinBUGS Version 1.4 User Manual, Medical Research Council Biostatics Unit, Cambridge, UK (2003).
19. Duffull, S.B., Kirkpatrick, C.M., Green, B. & Holford, N.H.G. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J. Biopharm. Stat. 15, 53-73 (2005).
20. Li, K.Y. et al Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol. Sin. 25, 390-394 (2004).
21. Dansirikul, C., Choi, M. & Duffull, S.B. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel. Comput. Biol. Med. 35, 389-403 (2005).
22. Spiegelhalter, D.J., Best, N.G., Carlin, B.R. & Van der Linde, A. Bayesian measures of model complexity and fit. J. R. Stat. Soc. Ser. B Stat. Methodol. 64, 583-616 (2002).
23. Friberg, L.E., Dansirikul, C. & Duffull, S.B. Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis. #100 (School of Pharmacy, University of Queensland, Brisbane, Australia, 2006).